R&D | June 10, 2026
FDA greenlights Lilly’s EBGLYSS for ultra-low-frequency dosing in eczema breakthrough
The move makes EBGLYSS the only therapy offering as few as six maintenance injections per year
The move makes EBGLYSS the only therapy offering as few as six maintenance injections per year
Researchers say the results point to a potential shift in how obesity is treated—as a central disease driving multiple conditions, rather than a collection of separate problems
Clears major obesity endpoints at 80 weeks
All three dose levels, 4 mg, 9 mg and 12 mg, successfully met the primary and key secondary endpoints in 80 weeks
Initiative focuses on early diagnosis, gut health awareness and long-term gluten-free care for children with celiac disease
Appointment strengthens Medanta’s pediatric super-specialty and respiratory care services in the Delhi-NCR region.
The perinatology CME at Navi Mumbai brought together more than 100 obstetricians, pediatricians, and neonatologists
Achondroplasia, a rare genetic disorder, causes skeletal dysplasia and often increases the risk of muscular, neurological, and cardiorespiratory complications
The NIRSE-GAL study, conducted in Galicia, Spain, is the first real-world, population-based investigation of a universal RSV immunization program spanning two consecutive seasons
The approval is grounded in data from a Phase III randomized, double-blind, placebo-controlled, crossover study in NPC patients
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
